Abstract
Randomised controlled trials uniformly show that lowering low-density lipoprotein (LDL) cholesterol results in a predictable and consistent reduction in coronary heart disease (CHD) events. The Heart Protection Study showed that the relative risk reduction in major vascular events was consistent irrespective of the LDL level at baseline. There appears to be no lower threshold level. Trials show that the greater the reduction in LDL, the greater the CHD risk reduction observed.
The management of dyslipidaemia is likely to follow the example of hypertension, such that the effective regulation of the lipid profile will be achieved by combination drug therapy.
Get full access to this article
View all access options for this article.